Ardena has announced the appointment of Paul Edwards as Chief People Officer. He will lead Ardena’s global people strategy, ...

Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults with moderate to severe active thyroid eye disease (T ...

CatalYm has dosed the first patient in its global GDFATHER-HCC-01 study, a phase 2b trial evaluating visugromab in combination with chemoimmunotherapy for people with unresectable or metastatic ...

Announcing the approval, UCB said Kygevvi is a 2g/2g powder for oral solution and represents the first therapy available in the European Union beyond supportive care. The company noted that TK2d ...

Viridian Therapeutics has announced encouraging topline results from its REVEAL‑1 phase 3 clinical trial evaluating ...

Indeed, from treatments that were once the stuff of science fiction to everyday products that have quietly transformed public ...

Kenneth Hobby, President of Cure SMA, said: “Nearly ten years ago, the approval of Spinraza marked a turning point in SMA ...

Laigo Bio has completed the second close of its seed financing round at €5.5m, bringing the total raised to €17m ...

Abselion has announced the appointment of Dale Gordon as Chair of the Board of Directors. His appointment strengthens ...

Structures change or revert, acronyms multiply and every incoming government promises transformation while discovering that ...

For much of modern medicine, healthcare systems have been structured around treating disease once it becomes clinically ...

Nearly one in ten adults in Great Britain have either recently used GLP-1 weight loss medications or are seriously ...